Introgen Wins Decision Against Schering-Plough At European Patent Office
Introgen Therapeutics Inc. said it won a patent battle with Schering-Plough Corp. that clears the path for commercialization of its Advexin cancer treatment in Europe....To view the full article, register now.
Already a subscriber? Click here to view full article